B-hPD-1/hPD-L1 mice(C)

BALB/cCrSlcNifdc-Pdcd1tm1(PDCD1)BcgenCd274tm1(CD274)Bcgen/Bcgen • 112489

B-hPD-1/hPD-L1 mice(C)

Catalog Number: 112489
Strain Name: BALB/cCrSlcNifdc-Pdcd1tm1(PDCD1)BcgenCd274tm1(CD274)Bcgen/Bcgen
Strain Background: BALB/cCrSlcNifdc
NCBI gene ID: 5133,29126 (Human)
Aliases: PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1; ADMIO4; AIMTBS; B7-H; B7H1; PDL1; PD-L1; ADMIO5; hPD-L1; PDCD1L1; PDCD1LG1
---
ライセンスオプション提供可能
B-hPD-1/hPD-L1 mice(C)

このページで

  • Description
  • Targeting strategy
  • Phenotypic analysis
  • Efficacy

ポスター

すべて表示

    出版物

      PD-1/PD-L1 MOA: PD-1/PD-L1 Functional Pathway and Therapeutic Blockade

      PD-1/hPD-L1: An immune-checkpoint and tumor-associated target for therapeutic intervention

      •Gene Information: PD-1 (PDCD1/CD279) is an inhibitory immune-checkpoint receptor. PD-L1 (CD274/B7-H1) is a key PD-1 ligand that mediates immune suppression in tumors and antigen-presenting-cell contexts.

      •Protein Expression: PD-1 is induced after antigen-specific T-cell stimulation and is often sustained during chronic activation. PD-L1 can be constitutively expressed by tumor cells or induced by IFN-γ and other inflammatory cues.

      •Signaling Pathway: PD-L1/PD-1 interaction initiates inhibitory signaling, including dephosphorylation events that suppress TCR downstream signaling. This reduces T-cell activation, cytotoxicity, and tumor-cell killing.

      •Therapeutic Inhibition: Anti-PD-1 or anti-PD-L1 monoclonal antibodies block the inhibitory interaction and restore cytotoxic T-cell activity. B-hPD-1/hPD-L1 mice(C) provide an in vivo platform for evaluating PD-1/PD-L1 checkpoint blockade and combination therapies.

      B-hPD-1/hPD-L1 Mice(C): Gene Targeting Strategy

      PD-1

      •A chimeric CDS including human PD-1 gene encoding the signal peptide and extracellular region, mouse PD-1 gene encoding the transmembrane and cytoplasmic region, a stop sequence WPRE were inserted after the initiation codon ATG of mouse PD-1 gene in B-hPD-1/hPD-L1 mice(C).

      •The endogenous mouse promoter and 5′ UTR are retained. The chimeric PD-1 expression is driven by the endogenous mouse PD-1 promoter, while endogenous mouse PD-1 transcription and translation are disrupted.

      PD-L1

      •Exon 3 of the mouse PD-L1 gene, which encode the IgV domain, was replaced with human PD-L1 exon 3 in B-hPD-1/hPD-L1 mice(C).

      •The endogenous mouse promoter, 5′ UTR, 3′ UTR, and genomic regions encoding the signal peptide, non-IgV domain of the Extracellular domain, transmembrane and cytoplasmic domains are retained. The chimeric PD-L1 expression is driven by the endogenous mouse PD-L1 promoter, while endogenous mouse PD-L1 transcription and translation are disrupted.

      B-hPD-1/hPD-L1 Mice(C): PD-1/PD-L1 Protein Expression Analysis

      •Mouse PD-1 and PD-L1 were detected in wild-type BALB/cCrSlcNifdc mice.

      •Human PD-1 and PD-L1 were detected in B-hPD-1/hPD-L1 mice(C) but not in wild-type mice.

      Strain-specific analysis of PD-1 protein expression in wild-type BALB/cCrSlcNifdc mice and homozygous B-hPD-1/hPD-L1 mice(C) by flow cytometry. Splenocytes were isolated from wild-type BALB/cCrSlcNifdc mice (+/+) and homozygous B-hPD-1/hPD-L1 mice(C) (H/H) and stimulated with anti-mouse CD3ε antibody. PD-1 expression was analyzed using anti-mouse PD-1 antibody (Biolegend, 109104) and anti-human PD-1 antibody (Biolegend, 329904). PD-L1 expression was analyzed using anti-mouse PD-1 antibody (Biolegend, 124312) and anti-human PD-1 antibody (Biolegend, 329706).

      B-hPD-1/hPD-L1 Mice(C): Spleen Leukocyte Subpopulation Analysis

      •Major splenic leukocyte subpopulations were comparable between B-hPD-1/hPD-L1 mice(C) and BALB/cCrSlcNifdc mice.

      Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were collected from female BALB/cCrSlcNifdc and B-hPD-1/hPD-L1 mice(C) (n=3, 7-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. The percentages of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes, and macrophages in homozygous B-hPD-1/hPD-L1 mice(C) were comparable to those in BALB/cCrSlcNifdc controls, indicating that PD-1 and PD-L1 humanization does not alter the overall development, differentiation, or distribution of these leukocyte populations in spleen. Values are expressed as mean ± SEM.

      B-hPD-1/hPD-L1 Mice(C): Spleen T-Cell Subpopulation Analysis

      •CD4+ T cells, CD8+ T cells and Tregs in spleen were comparable between B-hPD-1/hPD-L1 mice(C) and BALB/cCrSlcNifdc mice.

      Analysis of spleen T cell subpopulations by FACS. Splenocytes were isolated from female BALB/cCrSlcNifdc and B-hPD-1/hPD-L1 mice(C) (n=3, 7-week-old). Single live CD45+ cells were gated for the CD3+ T-cell population and used for further analysis. The percentages of CD4+ T cells, CD8+ T cells, and Tregs in homozygous B-hPD-1/hPD-L1 mice(C) were comparable to those in BALB/cCrSlcNifdc controls, indicating that replacement of mouse PD-1 with human PD-1 does not alter the overall development, differentiation, or distribution of these T-cell subtypes in spleen. Values are expressed as mean ± SEM.

      B-hPD-1/hPD-L1 Mice(C): Lymph Node Leukocyte Subpopulation Analysis

      •Major lymph node leukocyte subpopulations were comparable between B-hPD-1/hPD-L1 mice(C) and BALB/cCrSlcNifdc mice.

      Analysis of lymph node leukocyte subpopulations by FACS. Lymph nodes were isolated from female BALB/cCrSlcNifdc and B-hPD-1/hPD-L1 mice(C) (n = 3, 7-week-old). Single live cells were gated for the CD45+ population and used for further analysis. The percentages of T cells, B cells, CD4+ T cells, CD8+ T cells, Tregs, and NK cells in homozygous B-hPD-1/hPD-L1 mice(C) were comparable to those in BALB/cCrSlcNifdc controls, indicating that PD-1 and PD-L1 humanization does not alter the overall development, differentiation, or distribution of these immune-cell populations in lymph nodes. Values are expressed as mean ± SEM.

      B-hPD-1/hPD-L1 Mice(C): Lymph Node T-Cell Subpopulation Analysis

      •CD4+ T cells, CD8+ T cells and Tregs in lymph node were comparable between B-hPD-1/hPD-L1 mice(C) and BALB/cCrSlcNifdc mice.

      Analysis of lymph node T cell subpopulations by FACS. Lymph nodes were isolated from female BALB/cCrSlcNifdc and B-hPD-1/hPD-L1 mice(C) (n=3, 7-week-old). Single live CD45+ cells were gated for the CD3+ T-cell population and used for further analysis. The percentages of CD4+ T cells, CD8+ T cells, and Tregs in homozygous B-hPD-1/hPD-L1 mice(C) were comparable to those in BALB/cCrSlcNifdc controls, indicating that replacement of PD-1 and PD-L1 humanization does not alter the overall development, differentiation, or distribution of these T-cell subtypes in lymph nodes. Values are expressed as mean ± SEM.

      B-hPD-1/hPD-L1 Mice(C): Blood Leukocyte Subpopulation Analysis

      •Major blood leukocyte subpopulations were comparable between B-hPD-1/hPD-L1 mice(C) and BALB/cCrSlcNifdc mice.

      Analysis of blood leukocyte subpopulations by FACS. Blood cells were isolated from female BALB/cCrSlcNifdc and B-hPD-1/hPD-L1 mice(C) (n = 3, 7-week-old). Single live cells were gated for the CD45+ population and used for further analysis. The percentages of T cells, B cells, CD4+ T cells, CD8+ T cells, Tregs, and NK cells in homozygous B-hPD-1/hPD-L1 mice(C) were comparable to those in BALB/cCrSlcNifdc controls, indicating that PD-1 and PD-L1 humanization does not alter the overall development, differentiation, or distribution of these immune-cell populations in blood. Values are expressed as mean ± SEM.

      B-hPD-1/hPD-L1 Mice(C): Blood T-Cell Subpopulation Analysis

      •CD4+ T cells, CD8+ T cells and Tregs in blood were comparable between B-hPD-1/hPD-L1 mice(C) and BALB/cCrSlcNifdc mice.

      Analysis of blood T cell subpopulations by FACS. Blood cells were isolated from female BALB/cCrSlcNifdc and B-hPD-1/hPD-L1 mice(C) (n=3, 7-week-old). Single live CD45+ cells were gated for the CD3+ T-cell population and used for further analysis. The percentages of CD4+ T cells, CD8+ T cells, and Tregs in homozygous B-hPD-1/hPD-L1 mice(C) were comparable to those in BALB/cCrSlcNifdc controls, indicating that replacement of PD-1 and PD-L1 humanization does not alter the overall development, differentiation, or distribution of these T-cell subtypes in blood. Values are expressed as mean ± SEM.

      B-hPD-1/hPD-L1 Mice(C): Combination of Pembrolizumab Analog and ENT Effectively Inhibited Tumor Growth

      •Combination of pembrolizumab analog and ENT was efficacious in controlling tumor growth in B-hPD-1/hPD-L1 mice(C).

      Antitumor activity of combination of pembrolizumab analog (in-house) and entinostat (ENT) in B-hPD-1/hPD-L1 mice(C). (A) Combination of pembrolizumab analog and ENT inhibited B-hPD-L1 CT26.WT tumor growth in B-hPD-1/hPD-L1 mice(C). Murine colon cancer B-hPD-L1 CT26.WT cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1 mice(C) (female, 7-week-old, n=6). Mice were grouped when tumor volume reached approximately 60-80 mm3, at which time they were treated with pembrolizumab analog and ENT with doses indicated in panel; (B) Survival curve; (C) Body weight changes during treatment. B-hPD-1/hPD-L1 mice(C) provide a powerful preclinical model for in vivo evaluation of anti-human PD-1 antibodies and tumor microenvironment inhibitors. Values are expressed as mean ± SEM.

      * When publishing results obtained using this animal model, please acknowledge the source as follows: The animal model [B-hPD-1/hPD-L1 mice(C)] (Cat# 112489) was purchased from Biocytogen.